# Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients

> **NCT00303329** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 184 (actual)

## Conditions studied

- Anemia
- Hemosiderosis

## Interventions

- **DRUG:** Deferasirox

## Key facts

- **NCT ID:** NCT00303329
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 184 (ACTUAL)
- **Last updated:** 2011-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00303329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00303329, "Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00303329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*